Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:FIXX Homology Medicines (FIXX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Homology Medicines Stock (NASDAQ:FIXX) 30 days 90 days 365 days Advanced Chart Ad Crypto 101 MediaNext opportunity for crypto millions"Uptober" is here, and it's not just a clever name. Historically, October ignites crypto's most explosive gains. This year could be off the charts. Don't let this opportunity pass you by. In crypto, timing is everything. Go here to discover the #1 crypto set to dominate Uptober. Get Homology Medicines alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.33▼$16.8252-Week Range N/AVolume22,300 shsAverage Volume390,307 shsMarket Capitalization$978.01 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewHomology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.Read More… Next opportunity for crypto millions (Ad)"Uptober" is here, and it's not just a clever name. Historically, October ignites crypto's most explosive gains. This year could be off the charts. Don't let this opportunity pass you by. In crypto, timing is everything. Go here to discover the #1 crypto set to dominate Uptober. Receive FIXX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Homology Medicines and its competitors with MarketBeat's FREE daily newsletter. Email Address FIXX Stock News HeadlinesWhat Western medicine can learn from the ancient history of psychedelicsSeptember 13, 2024 | bbc.comOfficials in North Korea seek medicine for Kim Jong Un's health problems related to obesity, Seoul saysAugust 2, 2024 | nbcnews.comThis Crypto Is Set to Explode in OctoberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…October 12, 2024 | Crypto 101 Media (Ad)Homology Medicines, Inc.: Homology Medicines Declares Distribution to Common StockholdersMarch 24, 2024 | finanznachrichten.deFIXX Homology Medicines, Inc.March 23, 2024 | seekingalpha.comHomology Medicines Declares Distribution to Common StockholdersMarch 18, 2024 | finance.yahoo.comHOMOLOGY MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Homology Medicines, Inc. - FIXXFebruary 27, 2024 | businesswire.comHomology Medicines Inc (FIXX)February 2, 2024 | investing.comSee More Headlines FIXX Stock Analysis - Frequently Asked Questions How were Homology Medicines' earnings last quarter? Homology Medicines, Inc. (NASDAQ:FIXX) posted its quarterly earnings results on Monday, November, 15th. The company reported ($0.27) earnings per share for the quarter, topping analysts' consensus estimates of ($0.30) by $0.03. The company had revenue of $1.68 million for the quarter, compared to the consensus estimate of $0.63 million. Homology Medicines had a negative net margin of 4,779.31% and a negative trailing twelve-month return on equity of 102.52%. When did Homology Medicines' stock split? Shares of Homology Medicines split on Wednesday, March 20th 2024. The 2-1 split was announced on Wednesday, March 20th 2024. The newly issued shares were distributed to shareholders after the closing bell on Wednesday, March 20th 2024. An investor that had 100 shares of stock prior to the split would have 200 shares after the split. When did Homology Medicines IPO? Homology Medicines (FIXX) raised $100 million in an initial public offering (IPO) on Wednesday, March 28th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Evercore ISI acted as the underwriters for the IPO and BTIG was co-manager. What other stocks do shareholders of Homology Medicines own? Based on aggregate information from My MarketBeat watchlists, some other companies that Homology Medicines investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Enovix (ENVX), Luminar Technologies (LAZR), Advanced Micro Devices (AMD), Ginkgo Bioworks (DNA) and Tesla (TSLA). Company Calendar Last Earnings11/15/2021Today10/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:FIXX CUSIPN/A CIK1661998 Webwww.homologymedicines.com Phone(781) 301-7277FaxN/AEmployees7Year Founded2015Profitability EPS (Most Recent Fiscal Year)($1.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-112,960,000.00 Net Margins-4,779.31% Pretax Margin-7,532.87% Return on Equity-102.52% Return on Assets-74.91% Debt Debt-to-Equity RatioN/A Current Ratio7.25 Quick Ratio7.25 Sales & Book Value Annual Sales$1.16 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$1.26 per share Price / BookN/AMiscellaneous Outstanding Shares58,130,000Free Float48,774,000Market Cap$978.01 million OptionableOptionable Beta-0.10 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report This page (NASDAQ:FIXX) was last updated on 10/12/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe Crypto Whisperer Just Sounded the AlarmThe 2024 Altcoin Eruption is Almost Here (Get in by Nov. 4) In late 2020, Ian King urged his readers to tak...Banyan Hill Publishing | SponsoredDon’t Miss Out: Elon’s Game-Changing InventionWhen you click here you'll discover what Elon Musk's newest invention can do… And how it works… You migh...InvestorPlace | SponsoredNext opportunity for crypto millionsAs we enter crypto's golden quarter (October-December), this coin is primed for takeoff. The best part? Mos...Crypto 101 Media | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Homology Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Homology Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.